| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514400200 | Herpesviridae | 11 |
| 20100317568 | Anti-Viral Compounds - Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. | 12-16-2010 |
| 20100323952 | Nucleoside Analogs in Combination Therapy of Herpes Simplex Infections - A pharmaceutical product comprising a nucleoside analogue active against herpes simplex virus, such as acyclovir/valaciclovir or peniclovir/famciclovir, and an immunosuppressant, as a combined preparation for simultaneous, separate or sequential use in the treatment and/or prevention of herpes simplex virus infections. | 12-23-2010 |
| 20110230397 | PEPTIDES HAVING PHARMACOLOGICAL ACTIVITY FOR TREATING DISORDERS ASSOCIATED WITH ALTERED CELL MIGRATION, SUCH AS CANCER - Peptides and their functionally equivalent derivatives, in salified or non-salified form, with the general formula L | 09-22-2011 |
| 20120157376 | PHARMACOLOGICALLY ACTIVE ANTIVIRAL PEPTIDES AND METHODS OF THEIR USE - This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral infections. | 06-21-2012 |
| 20130005648 | PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING HERPESVIRUS INFECTION - The present invention provides an isolated peptide having an amino acid residue sequence that comprises at least one human cytomegalovirus glycoprotein B (HCMV-gB) sequence segment, each HCMV-gB sequence segment consisting of at least 8 and not more than 60 consecutive amino acid residues from residues 146 to 315, residues 476 to 494 of SEQ ID NO: 1, or from a sequence variant of residues 146 to 315 or 476 to 494 of SEQ ID NO: 1 that has at least 70% sequence identity thereto. The peptides of the invention are useful for treating, preventing, or inhibiting a herpesvirus (e.g., Herpes Simplex Virus-1, Human Cytomegalovirus, and the like) infection in a subject. | 01-03-2013 |
| 20130310309 | METHOD FOR TREATING DISORDERS OF THE SKIN - A topical pharmaceutical composition for treating a skin disorder selected from the group consisting of Herpes viral infection, Varicella viral infection, rash, insect bites, jellyfish stings, burns, psoriasis, itching, skin allergic response, skin lesions as a result of drug or medical treatment side effects or complications, and hypopigmantation. The composition comprises a peptide of the formula pGLU-X—Y—Z, where X, Y and Z are amino acids, with or without an alkyl group, and a pharmaceutically acceptable excipient. | 11-21-2013 |
| 20140087998 | USE OF PACAP FOR THE TREATMENT VIRAL INFECTIONS IN AQUATIC ORGANISMS - The present invention relates to the use of pituitary adenylate cyclase activating polypeptide (PACAP) in the treatment of viral diseases and infectious diseases caused by viruses in aquatic organisms. PACAP, alone or combined with an antiviral molecule, demonstrated its effectiveness by increasing the survival of fish or crustaceans infected by viruses when it was administered orally, by injection or by immersion baths. Furthermore, it was observed that treated organisms keep or increase its weight as compared to infected and non-treated organisms. PACAP or PACAP-containing combinations decreased the viral load in tissues and organs susceptible to viral infections as it was determined by RT-PCR. | 03-27-2014 |
| 20140128317 | ANTIVIRAL AGENT COMPRISING RECOMBINANT MISTLETOE LECTINS - The invention relates to an antiviral agent containing recombinant mistletoe lectins for treating virus infections and to a medicament and/or pharmaceutical composition for treating virus infections. | 05-08-2014 |
| 20150119318 | PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING HERPESVIRUS INFECTION - The present invention provides an isolated peptide having an amino acid residue sequence that comprises at least one human cytomegalovirus glycoprotein B (HCMV-gB) sequence segment, each HCMV-gB sequence segment consisting of at least 8 and not more than 60 consecutive amino acid residues from residues 146 to 315, residues 476 to 494 of SEQ ID NO: 1, or from a sequence variant of residues 146 to 315 or 476 to 494 of SEQ ID NO: 1 that has at least 70% sequence identity thereto. The peptides of the invention are useful for treating, preventing, or inhibiting a herpesvirus (e.g., Herpes Simplex Virus-1, Human Cytomegalovirus, and the like) infection in a subject. | 04-30-2015 |
| 20150343010 | Use Of A Casein Hydrolysate As An Antiherpetic Agent - The present invention relates to the use of a casein hydrolysate as an antiherpetic agent. This casein hydrolysate has an application in both the treatment and the prevention of the reactivation of a latent infection by a herpesvirus, and is effective both orally and topically. It also relates to a pharmaceutical composition in the form of cream, gel, ointment or paste for topical administration that contains it. | 12-03-2015 |
| 20160030519 | USE OF PACAP FOR THE TREATMENT OF VIRAL INFECTIONS IN AQUATIC ORGANISMS - The present invention relates to the use of pituitary adenylate cyclase activating polypeptide (PACAP) in the treatment of viral diseases and infectious diseases caused by viruses in aquatic organisms. PACAP, alone or combined with an antiviral molecule, demonstrated its effectiveness by increasing the survival of fish or crustaceans infected by viruses when it was administered orally, by injection or by immersion baths. Furthermore, it was observed that treated organisms keep or increase its weight as compared to infected and non-treated organisms. PACAP or PACAP-containing combinations decreased the viral load in tissues and organs susceptible to viral infections as it was determined by RT-PCR. | 02-04-2016 |
